---
title: lpsb
description: OpenBB Terminal Function
---

# lpsb

Print latest penny stock buys. [Source: OpenInsider]

### Usage

```python
lpsb [-l LIMIT]
```

---

## Parameters

| Name | Description | Default | Optional | Choices |
| ---- | ----------- | ------- | -------- | ------- |
| limit | Limit of datarows to display | 10 | True | None |


---

## Examples

```python
2022 Feb 16, 08:13 (ğŸ¦‹) /stocks/ins/ $ lpsb
                                                                                Insider Data
â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”³â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”“
â”ƒ X  â”ƒ Filing Date â”ƒ Trade Date â”ƒ Ticker â”ƒ Company Name      â”ƒ Insider Name         â”ƒ Title     â”ƒ Trade Type   â”ƒ Price â”ƒ Qty        â”ƒ Owned      â”ƒ Diff Own â”ƒ Value        â”ƒ
â”¡â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â•‡â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”©
â”‚ M  â”‚ 2022-02-16  â”‚ 2022-02-09 â”‚ ZIVO   â”‚ Zivo Bioscience,  â”‚ Maggiore Christopher â”‚ Dir, 10%  â”‚ P - Purchase â”‚ $3.72 â”‚ +91,334    â”‚ 803,105    â”‚ +13%     â”‚ +$340,098    â”‚
â”‚    â”‚ 06:02:09    â”‚            â”‚        â”‚ Inc.              â”‚ D.                   â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-15  â”‚ 2021-07-12 â”‚ VGZ    â”‚ Vista Gold Corp   â”‚ Sun Valley Gold      â”‚ 10%       â”‚ P - Purchase â”‚ $1.10 â”‚ +1,300,000 â”‚ 19,922,544 â”‚ +7%      â”‚ +$1,430,000  â”‚
â”‚    â”‚ 16:34:28    â”‚            â”‚        â”‚                   â”‚ Master Fund, Ltd     â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-14  â”‚ 2022-02-10 â”‚ SNSE   â”‚ Sensei            â”‚ Peyer James          â”‚ Dir, 10%  â”‚ P - Purchase â”‚ $4.45 â”‚ +17,500    â”‚ 5,175,786  â”‚ 0%       â”‚ +$77,900     â”‚
â”‚    â”‚ 19:19:52    â”‚            â”‚        â”‚ Biotherapeutics,  â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-14  â”‚ 2022-02-10 â”‚ SNSE   â”‚ Sensei            â”‚ Cambrian Biopharma   â”‚ 10%       â”‚ P - Purchase â”‚ $4.45 â”‚ +17,500    â”‚ 5,175,786  â”‚ 0%       â”‚ +$77,900     â”‚
â”‚    â”‚ 19:18:48    â”‚            â”‚        â”‚ Biotherapeutics,  â”‚ Inc                  â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-14  â”‚ 2022-02-10 â”‚ IMRA   â”‚ Imara Inc.        â”‚ Mott David M         â”‚ Dir       â”‚ P - Purchase â”‚ $1.23 â”‚ +31,826    â”‚ 31,826     â”‚ New      â”‚ +$39,246     â”‚
â”‚    â”‚ 17:02:52    â”‚            â”‚        â”‚                   â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-11  â”‚ 2022-02-09 â”‚ ARMP   â”‚ Armata            â”‚ Innoviva, Inc.       â”‚ Dir, 10%  â”‚ P - Purchase â”‚ $5.00 â”‚ +3,614,792 â”‚ 19,691,561 â”‚ +22%     â”‚ +$18,073,960 â”‚
â”‚    â”‚ 18:56:05    â”‚            â”‚        â”‚ Pharmaceuticals,  â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”‚    â”‚             â”‚            â”‚        â”‚ Inc.              â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-11  â”‚ 2022-02-09 â”‚ EMMA   â”‚ Emmaus Life       â”‚ Niihara Yutaka       â”‚ COB, CEO, â”‚ P - Purchase â”‚ $1.46 â”‚ +30,500    â”‚ 11,350,200 â”‚ 0%       â”‚ +$44,385     â”‚
â”‚    â”‚ 17:00:36    â”‚            â”‚        â”‚ Sciences, Inc.    â”‚                      â”‚ 10%       â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ M  â”‚ 2022-02-10  â”‚ 2022-02-08 â”‚ REVB   â”‚ Revelation        â”‚ Tidmarsh George F    â”‚ Dir, 10%  â”‚ P - Purchase â”‚ $2.55 â”‚ +31,000    â”‚ 1,970,491  â”‚ +2%      â”‚ +$79,139     â”‚
â”‚    â”‚ 18:22:45    â”‚            â”‚        â”‚ Biosciences, Inc. â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ D  â”‚ 2022-02-09  â”‚ 2022-02-08 â”‚ MYPS   â”‚ Playstudios, Inc. â”‚ Pascal Andrew S      â”‚ COB, CEO, â”‚ P - Purchase â”‚ $4.77 â”‚ +25,700    â”‚ 16,242,900 â”‚ 0%       â”‚ +$122,602    â”‚
â”‚    â”‚ 19:36:53    â”‚            â”‚        â”‚                   â”‚                      â”‚ 10%       â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â”œâ”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¼â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ AM â”‚ 2022-02-09  â”‚ 2022-02-04 â”‚ REVB   â”‚ Revelation        â”‚ Tidmarsh George F    â”‚ Dir, 10%  â”‚ P - Purchase â”‚ $2.56 â”‚ +52,000    â”‚ 1,939,491  â”‚ +3%      â”‚ +$132,936    â”‚
â”‚    â”‚ 16:24:52    â”‚            â”‚        â”‚ Biosciences, Inc. â”‚                      â”‚           â”‚              â”‚       â”‚            â”‚            â”‚          â”‚              â”‚
â””â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
A: Amended filing
D: Derivative transaction in filing (usually option exercise)
M: Multiple transactions in filing; earliest reported transaction date & weighted average transaction price
```
---
